ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1176

VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation

Tarek Dawamne1, Olivia Choi, MD, PhD, FAAD2, Alison Tran3, Jacob Beer4, Katelyn Rowland2, Theodore Alkousakis2, Oyediran Adelakun2, Elizabeth Skobelev2, Sancharitha Ramji2, Tony Ma5, Daphne Chan2 and Jenna Lester6, 1Texas A&M School of Engineering Medicine, Houston, TX, USA, Houston, TX, 2Johnson & Johnson, Horsham, PA, USA, Horsham, PA, 3Lake Granbury Medical Center, Department of Dermatology, Dallas, TX, USA, Dallas, TX, 4Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami, FL, USA, Miami, FL, 5Johnson & Johnson, Spring House, PA, USA, Spring House, PA, 6University of California, San Francisco, CA, USA, San Francisco, CA

Meeting: ACR Convergence 2025

Keywords: , , ,

Session Information

Date: Monday, October 27, 2025

Title: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Post-inflammatory pigment alteration (PIPA) following resolution of psoriasis plaques is an important, neglected problem that disproportionately impacts people of color.1-3 VISIBLE, an ongoing Phase 3b study evaluating guselkumab for moderate-to-severe psoriasis across all skin tones, is designed to collect PIPA data.

Methods: Total 211 participants were randomized (3:1) to receive guselkumab or placebo with placebo crossover to guselkumab at Weeks 16, 20, and every 8 weeks (q8w) thereafter. Through Week 48, clinician-reported Psoriasis Area Severity Index (PASI) responses and patient-reported outcomes (Skin Discoloration Impact Evaluation Questionnaire [SDIEQ], Dermatology Life Quality Index [DLQI], and Patient-Reported Outcomes Measurement Information System-29 [PROMIS-29]) were collected. Standard and cross-polarized photographs were obtained and analyzed for skin tone evenness.

Results: Mean PASI improvement was ~95% at Week 48 for the guselkumab randomized groups. Correlation coefficients were higher for SDIEQ and DLQI versus SDIEQ and PASI at Week 48, indicating high impact of skin discoloration on quality of life (QoL). SDIEQ had moderate (r=0.4116) and weak (r=0.3204) correlations with PROMIS-29 anxiety and depression measures, respectively, whereas Week 48 PASI did not correlate with either PROMIS-29 outcome.

Conclusion: Impact of PIPA on QoL is much greater than skin clearance as measured by PASI. Awareness of patient concerns about PIPA will enable clinicians to better counsel patients starting psoriasis treatment. The study is limited by variations in photograph quality. PIPA due to psoriasis highly impacts QoL in people of color. Discussing PIPA before starting treatment is imperative and its effect should be explicitly measured. While there are objective ways to quantify PIPA, further planned analyses of mechanistic changes will help identify factors predictive of PIPA outcomes.ReferencesAmico S, et al. J Am Acad Dermatol. 2020;83:1188-1191.Kauffman BP, et al. Am J Clin Dermatol. 2018;19:405-423.Chiu HY, et al. J Am Acad Dermatol. 2022;86:642-645.

Disclosures: T. Dawamne: None; O. Choi, MD, PhD, FAAD: Apogee Therapeutics Inc., 3, Johnson & Johnson, 11, 12, Employee of Johnson & Johnson at the time study was conducted; A. Tran: None; J. Beer: None; K. Rowland: Johnson & Johnson, 3, 11; T. Alkousakis: Johnson & Johnson, 3, 11; O. Adelakun: Johnson & Johnson, 3, 11; E. Skobelev: Johnson & Johnson, 3, 11; S. Ramji: Johnson & Johnson, 3, 11; T. Ma: Johnson & Johnson, 3, 11; D. Chan: Johnson & Johnson, 3, 11; J. Lester: Google, 2, L'Oreal, 2, Mattice biosciences, 1, OurX, 1.

To cite this abstract in AMA style:

Dawamne T, Choi, MD, PhD, FAAD O, Tran A, Beer J, Rowland K, Alkousakis T, Adelakun O, Skobelev E, Ramji S, Ma T, Chan D, Lester J. VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/visible-post-inflammatory-pigmentation-journeys-exploring-the-impact-of-pigmentation/. Accessed .

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/visible-post-inflammatory-pigmentation-journeys-exploring-the-impact-of-pigmentation/